Scynexis (SCYX) Change in Accured Expenses (2013 - 2026)
Scynexis' (SCYX) quarterly Change in Accured Expenses came in at -$1.4 million in Q1 2026, down 21.41% YoY from -$1.8 million in Q1 2025, and down 100.57% on a QoQ basis from -$704000.0 in Q4 2025.
Scynexis (SCYX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 21.41% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (up 73.86% YoY) and the FY2025 annual result came in at -$1.0 million, up 72.93% from the prior year.
- Change in Accured Expenses retreated to -$1.4 million in Q1 2026, from -$704000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $7.8 million in Q4 2023 to a low of -$5.8 million in Q1 2023.
- A 5-year average of -$254058.8 and a median of -$87000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 4991.84% — and 2025, when it jumped 1282.93%.
- Tracing SCYX's Change in Accured Expenses over 5 years: stood at -$2.5 million in 2022, then jumped by 414.31% to $7.8 million in 2023, then tumbled by 144.03% to -$3.5 million in 2024, then surged by 79.61% to -$704000.0 in 2025, then tumbled by 100.57% to -$1.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), -$704000.0 (Q4 2025), and -$105000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Scynexis | 61.90 Mn | -52.80 Mn | - | 655,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 655,000.00 |
| Jun 30, 2026 | 655,000.00 |
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | -704,000.00 |
| Dec 31, 2025 | -704,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Mar 31, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -87,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -82,000.00 |
| Jun 30, 2024 | -82,000.00 |
| Mar 31, 2024 | -79,000.00 |
| Mar 31, 2024 | -79,000.00 |